Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

CAPS Rating: 3 out of 5

The Company is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases.

Recs

0
Player Avatar Azulene (57.12) Submitted: 10/13/2008 6:43:28 AM : Outperform Start Price: $18.26 RIGL Score: -102.33

Drugs in pipeline

Featured Broker Partners


Advertisement